Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunic gets a "positive surprise" from lead asset trial

By: TheNewswire.com

Immunic Inc (NASDAQ: IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC).

Vitt describes it as "wonderful data" that came as a "positive surprise."

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  203.69
-3.27 (-1.58%)
AAPL  278.97
+5.29 (1.93%)
AMD  212.24
-1.33 (-0.62%)
BAC  54.73
-0.66 (-1.20%)
GOOG  312.28
-6.35 (-1.99%)
META  667.13
-3.59 (-0.54%)
MSFT  403.70
-9.57 (-2.32%)
NVDA  191.31
+2.77 (1.47%)
ORCL  155.69
-4.20 (-2.63%)
TSLA  424.75
-0.46 (-0.11%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.